Latest Pharmacy News

Pharmx Technologies Limited reported a 13% increase in revenue for FY25, driven by expanded supplier-pharmacy connections and Marketplace platform growth, while profit before tax declined due to significant investments in new technology platforms.

Argent BioPharma has signed a binding term sheet to acquire key assets from AusCann Group Holdings, significantly expanding its clinical pipeline, intellectual property, and European manufacturing and distribution capabilities ahead of a planned US stock exchange listing.

McPherson’s Limited has finalized a key pharmacy wholesaler agreement with API Services Australia, marking the completion of its new distribution model and transitioning significant revenue previously handled direct-to-store.

RooLife Group has secured a two-year supply agreement with Eternal Asia, granting access to over one million retail outlets across China and potential annual orders worth up to AUD 110 million.

Cann Group Limited delivered record production and revenue growth in Q4 FY2025, securing new funding and advancing a major debt restructuring to set the stage for profitability in FY2026.

Tissue Repair Limited reports steady progress in its Phase 3 clinical trials for TR987® despite patient recruitment hurdles, while TR Pro+® sales surge and new distribution deals pave the way for international growth.

Starpharma reports a 165% rise in FY25 customer receipts, advances its clinical-stage DEP® assets, and secures new distribution deals in Asia and Saudi Arabia.

MedAdvisor Solutions reported a 16.6% revenue decline in 4Q FY25, driven by US market challenges, while completing the sale of its ANZ business and initiating a strategic review of its US operations.

MedAdvisor reports a significant revenue decline in FY25 amid US program delays but strengthens its balance sheet through a capital raise and ANZ business sale. The company signals a strategic pivot with potential US business divestment on the horizon.

EVE Health Group has completed its acquisition of Nextract, raised $1 million to fund manufacturing, and achieved key regulatory and commercial milestones for its pharmaceutical products targeting erectile dysfunction and dysmenorrhea.

Biome Australia Limited has delivered record sales revenue in Q4 FY25 alongside positive EBITDA, setting the stage for its first full-year net profit. Strategic product launches and international expansion underpin its strong growth trajectory.

LTR Pharma has initiated commercial distribution of its nasal spray SPONTAN through Australia's Symbion pharmacy network and is advancing ROXUS development for a US launch in early 2026, while expanding its pipeline with a new intranasal treatment for swallowing disorders.